A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2018

At a glance

  • Drugs CWP 291 (Primary) ; Cytarabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors JW Pharmaceutical
  • Most Recent Events

    • 24 May 2018 Phase has been changed from I to I/II. Planned number of patients has also changed from 40 to 45.
    • 11 May 2018 Planned number of patients changed from 40 to 45.
    • 11 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top